Khaled Alabduljabbar

Dr. Khaled Alabduljabbar

King Faisal Specialist Hospital & Research Centre, Riyadh, Ar Riyāḑ, Saudi Arabia
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Middle East African Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
BABader Al-Qahtani
Bader Al-Qahtani
MAMohammed Al-Otaibi
Mohammed Al-Otaibi
Khaled AlabduljabbarKhaled Alabduljabbar
Khaled Alabduljabbar
NSNawafBin Selayem
NawafBin Selayem
WAWaleed Alshehri
Waleed Alshehri
SASaif Alsaif
Saif Alsaif
PURPOSE: The purpose of the study was to determine the incidence of retinopathy of prematurity (ROP) in preterm infants in the neonatal intensive care unit (NICU), to identify the risk factors that predispose to ROP, and to assess the outcome of these infants. MATERIALS AND METHODS: This was a retrospective cohort study on premature infants with a birth weight (BW) of <1501 g or gestational age (GA) of <32 weeks. These infants were admitted to the NICU at a tertiary hospital in Riyadh, Saudi Arabia, from January 2010 to December 2014. RESULTS: Five hundred and ninety-three infants were included; data were available for 581 infants. Of them, 224 infants (38.6%) had ROP. Of these, 22 infants (10.4%) had stage 3 ROP. The mean BW of infants with ROP was 938.4 ± 257.9 g, and the mean GA at birth was 27 ± 2.4 weeks. A significant relationship with a P <0.05 was found between the occurrence of ROP and small GA at birth, low BW, low APGAR score at 1 min, and long duration of receiving oxygen (O2) therapy. Based on charts review, none of the infants had blindness. CONCLUSION: The incidence of ROP in our study falls in the range of incidence in developing countries. The low BW and small GA were the most significant risk factors. Furthermore, it is also recommended to control the amount and duration of O2therapy to as little as needed.

26 May 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Khaled AlabduljabbarKhaled Alabduljabbar
Khaled Alabduljabbar
WAWerd Al-Najim
Werd Al-Najim
Carel W. Le RouxCarel W. Le Roux
Carel W. Le Roux
Obesity is a complex and chronic disease that raises the risk of various complications. Substantial reduction in body weight improves these risk factors. Lifestyle changes, including physical activity, reduced caloric ingestion, and behavioral therapy, have been the principal pillars in the management of obesity. In recent years, pharmacologic interventions have improved remarkably. The Semaglutide Treatment Effect in People with Obesity (STEP) program is a collection of phase-III trials geared toward exploring the utility of once-weekly 2.4 mg semaglutide administered subcutaneously as a pharmacologic agent for patients with obesity. All the STEP studies included diet and exercise interventions but at different intensities. This review paper aims to explore the impact of the behavioral programs on the effect of semaglutide 2.4 mg on weight loss. The results of the STEP trials supported the efficacy of high-dose, once-weekly 2.4 mg semaglutide on body weight reduction among patients with obesity with/without diabetes mellitus. Semaglutide was associated with more gastrointestinal-related side effects compared to placebo but was generally safe and well tolerated. In all the STEP studies, despite the varying intestines of the behavioral programs, weight loss was very similar. For the first time, there may be a suggestion that these behavioral programs might not increase weight reduction beyond the effect of semaglutide. Nevertheless, the importance of nutritional support during substantial weight loss with pharmacotherapy needs to be re-evaluated.

18 September 2023 in Metabolism
Verified
Journal Article
Closed access
Khaled AlabduljabbarKhaled Alabduljabbar
Khaled Alabduljabbar
Carel W. Le RouxCarel W. Le Roux
Carel W. Le Roux

25 April 2021 in Saudi Medical Journal
Verified
Journal Article
Open access
PDF file
MAMohammed K. Alkhalifah
Mohammed K. Alkhalifah
Khaled AlabduljabbarKhaled Alabduljabbar
Khaled Alabduljabbar
AAAbdullah research Alkhenizan
Abdullah research Alkhenizan
Objectives: To evaluate the available evidence of natural honey and its effect on improving lipid profiles among the adult population. Methods: The following databases were searched in May 2020 for randomized controlled trials (RCTs) and crossover studies without any restrictions in language, publication year, or status: CENTRAL, Embase Elsevier, ClinicalTrials.gov, MEDLINE, the WHO International Clinical Trials Registry Platform, and Google Scholar. We included all RCTs and crossover studies that studied the effect of natural honey on improving lipid levels in individuals at any age, for any dose and duration. Trials investigated the intake of honey alone or honey dissolved in water. The comparison groups were no intervention or placebo. Two independent reviewers screened and evaluated the included trials. The third reviewer was involved in resolving any disagreement. Our aim was to evaluate the evidence available regarding the effect of natural honey in improving lipid profile. Results: Seven trials with 370 participants fitted the inclusion criteria. Pooled analysis showed, honey was found to reduce total cholesterol levels with statistical significance (mean difference [MD]: -14.97 mg/dl, 95% CI: 19.61 to -10.32). Honey was associated with a statistically significant increase in high-density lipoprotein (HDL) levels (MD: 1.78 mg/dl, 95% CI: 0.68 to 2.88). There was a statistically significant LDL reduction level (MD: 18.99 mg/dl, 95% CI: -22.79 to -15.20). Finally, honey was found to lower triglyceride levels significantly (MD: 9.68 mg/dl, 95% CI: -15.56 to -3.80). Conclusions: Total cholesterol was significantly reduced with the use of natural honey intake, as well as low-density lipoprotein (LDL), and triglycerides. High-density lipoprotein showed significant increment. Small quantity of honey can be recommended for patients with dyslipidemia. The impact on clinical outcomes such as cardiovascular mortality and morbidity needs to be evaluated in large studies. PROSPERO REG. NO. CRD: 42020130741

4 September 2023 in Gastroenterology Clinics of North America
Verified
Journal Article
Closed access
Khaled AlabduljabbarKhaled Alabduljabbar
Khaled Alabduljabbar
EBEfstathios Bonanos
Efstathios Bonanos
AMAlexander D. Miras
Alexander D. Miras
Carel W. Le RouxCarel W. Le Roux
Carel W. Le Roux

14 August 2022 in Saudi Medical Journal
Verified
Journal Article
Open access
PDF file
ASAbdulelah S. Bin Shihah
Abdulelah S. Bin Shihah
AAAbdulrahman H. Alrashed
Abdulrahman H. Alrashed
Khaled AlabduljabbarKhaled Alabduljabbar
Khaled Alabduljabbar
HAHassan A. Alamri
Hassan A. Alamri
MSMohammed Shafiq
Mohammed Shafiq
KAKhaled Alabduljabbar
Khaled Alabduljabbar
Objectives: To determine the level of awareness of medical law among healthcare practitioners and to identify factors that influence that level of awareness in Saudi Arabia. Methods: This cross-sectional study was carried out in Riyadh, Saudi Arabia in 2020-2021 via a survey including 750 healthcare practitioners, from different specialties including all regions in Saudi Arabia. Participants included consultants, senior registrars, interns, and residents. Results: Majority of enrolled healthcare practitioners had poor awareness of medical law (approximately 97%). Only 1.5% had adequate awareness of medical law, and only 1.5% had moderate awareness. Factors associated with increased medical law awareness were the age group between 25 and 34, being from the central region, and having a clinical practice for less than 10 years p-value of <0.05. Conclusion: Awareness of medical law among healthcare practitioners is limited in Saudi Arabia. Professional medico-legal education should be part of required competencies for undergraduate and postgraduate levels of medical education. Health care practitioners must be educated with laws and regulations of practicing health professions in the country.